Key Takeaways
Newlimit raised a $435 million Collection C led by Founders Fund, introduced June 2.The spherical lifted the biotech’s valuation to about $3.1 billion, roughly triple its prior mark.Newlimit plans to deliver its first cell-aging reprogramming medication into human trials subsequent 12 months.
Crypto Wealth Flows Into Longevity Science
Newlimit, the anti-aging biotech co-founded by Coinbase International Inc. (Nasdaq: COIN) Chief Govt Brian Armstrong, has closed a $435 million Collection C funding spherical, the corporate introduced on June 2. The increase was led by Founders Fund and roughly tripled Newlimit’s post-money valuation to about $3.1 billion, up from a mark that sat under $1 billion at its earlier spherical.
The financing drew a roster of high-profile backers, together with new buyers like Thrive Capital, Greenoaks, and Quiet Capital. Returning supporters included Kleiner Perkins, Summary, and Valor Fairness Companions, every of whom added to their current stakes.
Based in 2021 by Armstrong, former GV accomplice and bioengineer Blake Byers, and stem cell biologist Mark Kimmel, Newlimit is constructed on a single thesis, i.e. getting old is “plastic,” or reversible, on the mobile stage. The corporate develops medicines designed to revive youthful perform to previous cells by way of epigenetic reprogramming, a method that goals to reset how genes are expressed with out altering the underlying DNA.
From a Facet Undertaking to a $3 Billion Guess
Newlimit has grown rapidly and the numbers spell that fairly clearly. The startup raised $130 million as not too long ago as final 12 months, that means the brand new spherical greater than triples its valuation in roughly twelve months. The corporate has mentioned the accelerated timeline was pushed by a prototype medication breakthrough that reverses cell age in previous human liver cells, giving the workforce confidence to push towards the clinic.
That progress units up the corporate’s most essential milestone but, as Newlimit mentioned it plans to deliver its first aging-reprogramming medication into human scientific trials subsequent 12 months, a step that may transfer the agency from laboratory analysis into regulated drug improvement.
Furthermore, epigenetic reprogramming, the science underpinning Newlimit, has turn into one of the vital intently watched and closely funded areas of biotechnology. The method builds on Nobel-winning analysis exhibiting that mature cells could be coaxed again towards a youthful state, and a wave of startups has raced to show that perception into therapies. Newlimit’s newest increase locations it among the many best-capitalized names within the area.
Armstrong’s Increasing Footprint
For Armstrong, the spherical highlights a portfolio that now stretches properly past Coinbase. He has used his crypto fortune to again bold science and infrastructure initiatives, framing longevity as one of many defining technological challenges of the period. Bitcoin.com Information has reported on Armstrong’s operating commentary about modernizing finance and the broader onchain financial system, and his biotech guess runs on a parallel monitor of long-horizon, high-risk investing.
The Founders Fund-led spherical additionally displays renewed investor urge for food for moonshot biotech at a time when crypto markets have been wobbling. Backers are betting that breakthroughs in mobile reprogramming may ultimately produce remedies for age-related illness, a market measured within the trillions if the science delivers.
The subsequent check is the clinic and Newlimit’s transfer into human trials subsequent 12 months would be the first real-world learn on whether or not its laboratory outcomes translate into protected, efficient medicines.
